1. Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells.
- Author
-
Flahou C, Morishima T, Higashi N, Hayashi Y, Xu H, Wang B, Zhang C, Ninomiya A, Qiu WY, Yuzuriha A, Suzuki D, Nakamura S, Manz M, Kaneko S, Hotta A, Takizawa H, Eto K, and Sugimoto N
- Subjects
- Humans, Animals, Mice, Killer Cells, Natural, Histocompatibility Antigens Class I metabolism, T-Lymphocytes, HLA Antigens metabolism, Induced Pluripotent Stem Cells
- Abstract
Human induced pluripotent stem cells (hiPSCs) genetically depleted of human leucocyte antigen (HLA) class I expression can bypass T cell alloimmunity and thus serve as a one-for-all source for cell therapies. However, these same therapies may elicit rejection by natural killer (NK) cells, since HLA class I molecules serve as inhibitory ligands of NK cells. Here, we focused on testing the capacity of endogenously developed human NK cells in humanized mice (hu-mice) using MTSRG and NSG-SGM3 strains to assay the tolerance of HLA-edited iPSC-derived cells. High NK cell reconstitution was achieved with the engraftment of cord blood-derived human hematopoietic stem cells (hHSCs) followed by the administration of human interleukin-15 (hIL-15) and IL-15 receptor alpha (hIL-15Rα). Such "hu-NK mice" rejected HLA class I-null hiPSC-derived hematopoietic progenitor cells (HPCs), megakaryocytes and T cells, but not HLA-A/B-knockout, HLA-C expressing HPCs. To our knowledge, this study is the first to recapitulate the potent endogenous NK cell response to non-tumor HLA class I-downregulated cells in vivo. Our hu-NK mouse models are suitable for the non-clinical evaluation of HLA-edited cells and will contribute to the development of universal off-the-shelf regenerative medicine., Competing Interests: Declaration of competing interest H.X., S.N., A.H., K.E., and N.S. have applied for patents related to this manuscript. K.E. is a founder of Megakaryon and a member of its scientific advisory board without salary. N.S. serves as an advisory for Megakaryon. S. Kaneko is a founder, shareholder, and director at Thyas Co., Ltd., and received research funding from Takeda Pharmaceutical Co., Ltd., Thyas Co., Ltd., Astellas Co., Ltd., KOTAI biotechnologies Co., Ltd., and Terumo Co., Ltd. This work was supported in part by grants from Megakaryon and Otsuka Pharmaceuticals. These interests were reviewed and are managed by Kyoto University in accordance with its conflict-of-interest policies., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF